Aquestive Therapeutics is trading at $4.04, up 5.35%, with biotech-sector strength providing supportive context; the cause of today’s move is unconfirmed. - No new company-specific announcement was found for October 20. - The FDA’s acceptance of the Anaphylm NDA resubmission and March 16, 2027 PDUFA date were announced October 15. - The XBI rose 2.10% during the regular session.